Lemontas Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, which play a key role in airway inflammation and bronchoconstriction, making it effective in preventing asthma symptoms and improving respiratory function. The synergistic action of these agents provides comprehensive relief from allergic manifestations by targeting multiple inflammatory pathways. Lemontas is typically administered once daily, with or without food, and is well tolerated in both adults and adolescents. Common adverse effects may include headache, fatigue, and gastrointestinal disturbances, though serious side effects are rare. It is contraindicated in patients with known hypersensitivity to either component. Caution is advised in patients with hepatic impairment or a history of neuropsychiatric events. Lemontas Tablet offers an effective therapeutic option for patients requiring combined antihistaminic and leukotriene receptor antagonist therapy to achieve optimal control of allergic symptoms and improve quality of life.